COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Eunkyung An, Ph.D.

Program Officer

Dr. Eunkyung An

Dr. An is a Program Officer in the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), National Institutes of Health (NIH). She provides scientific expertise in Clinical Proteomics, Oncology and Precision medicine to new and existing OCCPR programs.

Prior to joining OCCPR, Dr. An served as an advisor to scientific and technical personnel in wide area of scientific subject matters including technology transfer of mass spec-based clinical proteomics assays and cancer clinical proteomics research (SCLC and RC) as a manager at mProbe; lead and managed multiple international oncology projects (GC, NSCLC, and CRC) and qualified numerus LC-MS/MS platforms to analyze FFPE tumor tissues from cancer patients in CAP/CLIA laboratory as a Sr. Scientist at NantOmics; and developed mass spec-based assays for cancer clinical research and cancer diagnosis as a scientist at OncoPlex Dx.

Dr. An completed undergraduate training in Biology at Sungshin Women's University, S. Korea, holds both a MS degree in Genomics, Proteomics, and Bioinformatics and Ph.D. degree in Biochemistry and Molecular Genetics from the George Washington University, and completed postdoctoral training in the Laboratory of Immune System Biology at the NIAID.